CureVac stories promising COVID-19 vaccine trial outcomes with GSK

FRANKFURT – CureVac has not too long ago shared encouraging outcomes from its newest COVID-19 vaccine trials, carried out in partnership with GSK. The preliminary knowledge signifies that the vaccines, together with a monovalent and a bivalent candidate, have generated sturdy immune responses even with decrease dosages and are well-tolerated.

The monovalent vaccine candidate is designed to focus on the spike protein of the Omicron BA.4-5 variant, whereas the bivalent vaccine candidate goals on the spike proteins of each the Omicron BA.4-5 variant and the unique SARS-CoV-2 virus. These outcomes mark a big step ahead within the ongoing efforts to develop efficient vaccines towards rising variants of COVID-19.

As the corporate pronounces these optimistic trial outcomes, it’s also getting ready for discussions about advancing to a Section 3 trial. This subsequent part is essential for additional evaluating the efficacy and security of the vaccine candidates on a bigger scale. The development to Section 3 will convey the vaccines one step nearer to potential approval and public availability.

This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.